"The single VAP Test reports over 20 separate values, including apoB, eliminating the need for nine separate tests that would have to be run in a typical laboratory setting," commented Mullen. "The VAP Test is now well positioned to be the market leader in advanced lipid testing. It has the comprehensive lipid reporting that an increasing number of physicians and practices are requesting without the added cost, which fits nicely in our current economic and health care environment."
Mullen said the patent should have a positive impact on his company's business.
"We expect to see an increase in orders for our VAP Test because of its clinically validated ability to accurately report apoB and because it is quickly becoming more of a standard in determining heart disease risk in cholesterol testing."
The VAP Test is available nationwide and covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit www.thevaptest.com.
About Atherotech, Inc.
Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert
|SOURCE Atherotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved